Freeline Therapeutics Holdings PLC (FRLN)
| Market Cap | 632.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 33.23M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $18.20 |
| Previous Close | $18.10 |
| Change ($) | 0.10 |
| Change (%) | 0.55% |
| Day's Open | 17.68 |
| Day's Range | 17.66 - 18.20 |
| Day's Volume | 2,522 |
| 52-Week Range | 14.94 - 18.30 |
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...
Updated dose-ranging data demonstrate potential for full normalization of FIX activity
LONDON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...
LONDON, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-bas...
About FRLN
Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to ... [Read more...]
| Industry Biotechnology | IPO Date Aug 7, 2020 |
| CEO Theresa Marie Heggie | Employees 200 |
| Stock Exchange NASDAQ | Ticker Symbol FRLN |
Analyst Forecasts
According to 5 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 28.75, which is an increase of 57.97% from the latest price.